(Q36092031)

English

Impact of immunohistochemistry-based molecular subtype on chemosensitivity and survival in patients with breast cancer following neoadjuvant chemotherapy

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Impact of immunohistochemistry-based molecular subtype on chemosensitivity and survival in patients with breast cancer following neoadjuvant chemotherapy (English)

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

1 reference

based on heuristic

inferred from title

immunohistochemistry

1 reference

based on heuristic

inferred from title

author name string

Changhoon Yoo

1

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Jin-Hee Ahn

2

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Kyung Hae Jung

3

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Sung-Bae Kim

4

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Hak-Hee Kim

5

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Hee Jung Shin

6

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Sei Hyun Ahn

7

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Byung Ho Son

8

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Gyungyub Gong

9

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

publication date

28 June 2012

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Journal of breast cancer

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

15

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

2

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

203-210

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

copyright license

Creative Commons Attribution-NonCommercial 3.0 Unported

1 January 2012

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395744

2 October 2017

Triple negative breast cancers: clinical and prognostic implications.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395744

2 October 2017

Gene expression predictors in breast cancer: current status, limitations and perspectives

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395744

2 October 2017

Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395744

2 October 2017

Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395744

2 October 2017

Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395744

2 October 2017

Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395744

2 October 2017

Molecular portraits of human breast tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395744

2 October 2017

Prognostic and predictive factors in breast cancer by immunohistochemical analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395744

2 October 2017

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395744

27 July 2018

Breast cancer molecular subtypes respond differently to preoperative chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395744

27 July 2018

Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395744

27 July 2018

Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395744

23 September 2018

Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395744

23 September 2018

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395744

23 September 2018

Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395744

23 September 2018

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395744

23 September 2018

Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395744

23 September 2018

Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395744

23 September 2018

Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395744

21 October 2018

Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast

1 reference

https://pubmed.ncbi.nlm.nih.gov/22807938

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22807938

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22807938

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.4048/JBC.2012.15.2.203

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

release_77yoi47vofdglcsjbmxpzobeka

1 reference

https://api.fatcat.wiki/v0/release/77yoi47vofdglcsjbmxpzobeka

24 November 2022

based on heuristic

mapped directly with Wikidata item

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36092031&oldid=1987826321"